Study of retlirafusp alfa plus chemo for stomach cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called retlirafusp alfa combined with chemotherapy as a treatment before and after surgery for a specific type of stomach cancer. It aims to see if this combination is safe and effective for patients whose cancer has a high level of a certain protein (CPS > 5) and is not driven by HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of stomach cancer called adenocarcinoma of the gastroesophageal junction (where the stomach meets the esophagus).
- Your cancer must have a CPS score higher than 5 and be HER2-negative.
- Your cancer must be at a stage where it is considered locally advanced but can still be surgically removed (Siewert type I or II).
- You should be between 18 and 75 years old and in good overall health (ECOG score 0-1).
- You cannot have received any previous cancer treatment like chemotherapy, radiation, or immunotherapy.
- You must have adequate organ function, including good heart, liver, kidney, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Retlirafusp Alfa) combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow surgery, and is for patients with specific types of HER2-negative or low-HER2 cancer and a PD-L1 CPS score of 1 or higher.
This trial tests a new drug combination (retlirafusp alfa plus chemotherapy) against a standard immunotherapy (PD-1 inhibitor) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and who haven't had prior treatment for advanced disease.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug (retlirafusp alfa) combined with standard chemotherapy given before surgery to treat esophageal squamous cell carcinoma—a type of cancer in the food tube. The goal is to shrink the tumor before removal and improve outcomes.
This trial tests a new drug called retlirafusp alfa combined with standard chemoradiotherapy for people with esophageal cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests whether giving Relatrilfa-α (a new immunotherapy) combined with chemotherapy before surgery can help shrink stage II–III lung cancer tumors and improve surgical outcomes. You would receive two rounds of this combination treatment, then have surgery to remove the tumor.
Hear when a new GEJ Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.